Patent US1681839A successfully refreshed from Google Patents.
← Back to Patent Explorer
US5656446A Expired / Lapsed US ⏱️ 0.0 years remaining

Method for the assessment of the mononuclear leukocyte immune system

Assignee: LYMPHOCYTE KINETICS Inc
•
Filing: 1995-03-17
•
Granted: 1997-08-12
•
Expires: 2015-03-17
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The ability of mononuclear leukocytes to respond to standard stimuli is measured based on the expression of activation antigens on mononuclear cell subclasses. In a preferred embodiment, a sample of mononuclear leukocytes is cultured for up to 24 hours with a standard stimulus known to activate such cells. After culturing, aliquots of the cells are incubated with fluorophore-conjugated monoclonal antibodies to antigenic determinants of a particular mononuclear subclass and different fluorophore-conjugated monoclonal antibodies to particular activation antigens. The incubated aliquots are analyzed on a flow cytofluorometer, whereby each cell is illuminated with a particular light (e.g. argon ion laser), which detects and measures forward light scatter, orthogonal light scatter and two different wavelengths of light emitted from the fluorophores. These parameters are used to identify and enumerate the cells of different subclasses present within the mononuclear leukocyte sample, the cells of said subclasses which have been induced to express a particular activation antigen and the quantity of the activation antigen on said cells. An analysis of these enumerations is shown to correlate with the immunoregulatory status of the mononuclear leukocyte immune system. Data generation and analysis can be performed using a flow cytofluorometric apparatus with data and control signal processing to ensure accuracy and reproducibility of the results of the assay.

Inventors

  • 👤 Jeffrey E. Anderson

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-05 13:53
CPC Classifications
G; G01; G01N; G01N15/00; G01N15/10; G01N15/14; G01N15/1456; G01N33/00; G01N33/48; G01N33/50; G01N33/5005; G01N33/5091; G01N33/53; G01N33/569; G01N33/56966; G01N33/56972; G01N33/56983; G01N33/56988; C; C12; C12M; C12M41/00; C12M41/46; G01N15/1468; G01N15/147; G01N15/01; G01N2015/016; G01N21/00; G01N21/62; G01N21/63; G01N21/64; G01N21/6428; G01N2021/6439

Claims Analysis

Total Claims: 21
Claim 1
Independent Claim 98 words
A method for monitoring or diagnostically detecting the in vivo immunoregulatory status of a mammal with an immune-mediated disorder comprising: (a) culturing a sample of peripheral mononuclear cells from a mammal who has an immune-mediated disorder with a standard stimulus for up to 24 hours; (b) measuring an aliquot of said cultured sample for the percentage of at least one subclass of mononuclear cells expressing activation antigen in vitro; and (c) comparing said percentage with a predetermined level of said percentage as an indicator of said in vivo immunoregulatory status of said mammal with said immune mediated disorder.
Claim 2
Independent Claim 98 words
A method for monitoring or diagnostically detecting the in vivo immunoregulatory status of a mammal with an immune-mediated disorder comprising: (a) culturing a sample of peripheral mononuclear cells from a mammal who has an immune-mediated disorder with a standard stimulus for up to 24 hours; (b) measuring an aliquot of said cultured sample for the percentage of at least one subclass of mononuclear cells expressing activation antigen in vitro; and (c) comparing said percentage with a predetermined level of said percentage as an indicator of said in vivo immunoregulatory status of said mammal with said immune mediated disorder.
Claim 3
Dependent Claim 13 words
The method of claim 1 wherein said mammal has received an organ transplant.
Claim 4
Dependent Claim 11 words
The method of claim 1 wherein said mammal has a malignancy.
Claim 5
Dependent Claim 12 words
The method of claim 1 wherein said mammal has an autoimmune disease.
Claim 6
Dependent Claim 14 words
The method of claim 1 wherein said mammal has an infection with a virus.
Claim 7
Dependent Claim 11 words
The method of claim 5 wherein said virus is HTLV III.
Claim 8
Dependent Claim 11 words
The method of claim 1 wherein said activation antigen is IL2R.
Claim 9
Dependent Claim 15 words
The method of claim 1 wherein said subclass of mononuclear cells is natural killer cells.
Claim 10
Dependent Claim 15 words
The method of claim 1 wherein said subclass of mononuclear cells is helper/inducer T lymphocytes.
Claim 11
Dependent Claim 15 words
The method of claim 1 wherein said subclass of mononuclear cells is suppressor/cytotoxic T lymphocytes.
Claim 12
Dependent Claim 15 words
The method of claim 1 wherein said subclass of mononuclear cells is suppressor T lymphocytes.
Claim 13
Dependent Claim 15 words
The method of claim 1 wherein said subclass of mononuclear cells is cytotoxic T lymphocytes.
Claim 14
Dependent Claim 15 words
The method of claim 1 wherein said subclass of mononuclear cell's is helper T lymphocytes.
Claim 15
Dependent Claim 15 words
The method of claim 1 wherein said subclass of mononuclear cells is inducer T lymphocytes.
Claim 16
Dependent Claim 11 words
The method of claim 1 wherein said mammal is a patient.
Claim 17
Dependent Claim 52 words
The method of claim 1 wherein said predetermined level is obtained from culturing a sample of peripheral mononuclear cells from a mammal with a standard stimulus for up to 24 hours and measuring said cultured sample for the percentage of at least one subclass of mononuclear cells expressing activation antigen in vitro.
Claim 18
Dependent Claim 50 words
The method of claim 1 wherein said predetermined level is obtained from culturing a sample of peripheral mononuclear cells from said mammal who has previously had said immune-mediated disorder and measuring said cultured sample for the percentage of at least one subclass of mononuclear cells expressing activation antigen in vitro.
Claim 19
Dependent Claim 49 words
The method of claim 1 wherein said predetermined level is obtained from culturing a sample of peripheral mononuclear cells from a mammal who has previously had immune-mediated disorder and measuring said cultured sample for the percentage of at least one subclass of mononuclear cells expressing activation antigen in vitro.
Claim 20
Dependent Claim 18 words
The method of claim 1 wherein measuring said subclass is performed using at least one fluorophore-conjugated monoclonal antibody.
Claim 21
Dependent Claim 19 words
The method of claim 1 wherein measuring said activation antigen is performed using at least one fluorophore-conjugated monoclonal antibody.

References Cited (Backward Citations)

US4381295A Cited
US4284412A Cited
US4520110A Cited
US4492752A Cited
US4607007A Cited
US4599304A Cited
US4701408A Cited
US4677061A Cited
US4727020A Cited
US4778750A Cited
US5445939A Cited
EP0325489A1 Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 2000-08-11 2001-02-10 2001-08-12 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2004-08-11 2005-02-10 2005-08-12 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2008-08-11 2009-02-10 2009-08-12 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag